HK1219902A1 - 生物合成的脯氨酸/丙氨酸無規捲曲多肽及其用途 - Google Patents
生物合成的脯氨酸/丙氨酸無規捲曲多肽及其用途Info
- Publication number
- HK1219902A1 HK1219902A1 HK16108081.5A HK16108081A HK1219902A1 HK 1219902 A1 HK1219902 A1 HK 1219902A1 HK 16108081 A HK16108081 A HK 16108081A HK 1219902 A1 HK1219902 A1 HK 1219902A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- random coil
- coil polypeptides
- proline alanine
- biosynthetic
- alanine random
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
- C07K14/615—Extraction from natural sources
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10163564 | 2010-05-21 | ||
US201061428016P | 2010-12-29 | 2010-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1219902A1 true HK1219902A1 (zh) | 2017-04-21 |
Family
ID=42629445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16108081.5A HK1219902A1 (zh) | 2010-05-21 | 2016-07-11 | 生物合成的脯氨酸/丙氨酸無規捲曲多肽及其用途 |
Country Status (19)
Country | Link |
---|---|
US (3) | US9221882B2 (zh) |
EP (2) | EP2571510B1 (zh) |
JP (2) | JP5828889B2 (zh) |
KR (1) | KR101872541B1 (zh) |
CN (2) | CN102883734B (zh) |
AU (1) | AU2011254564B2 (zh) |
BR (1) | BR112012029577B1 (zh) |
CA (1) | CA2794614C (zh) |
DK (1) | DK2571510T3 (zh) |
EA (1) | EA024755B1 (zh) |
ES (1) | ES2691642T3 (zh) |
HK (1) | HK1219902A1 (zh) |
LT (1) | LT2571510T (zh) |
MX (2) | MX338914B (zh) |
NZ (1) | NZ602522A (zh) |
PL (1) | PL2571510T3 (zh) |
SG (1) | SG185440A1 (zh) |
SI (1) | SI2571510T1 (zh) |
WO (1) | WO2011144756A1 (zh) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102883734B (zh) | 2010-05-21 | 2018-01-02 | Xl-蛋白有限责任公司 | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 |
CA2843504C (en) * | 2011-08-12 | 2020-08-25 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
CA2869460C (en) | 2012-04-04 | 2018-05-15 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
US10066007B2 (en) | 2013-01-22 | 2018-09-04 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
JP6259209B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | コラーゲン産生促進剤 |
JP6259208B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | ヒアルロン酸産生促進剤 |
JP6259207B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | エラスチン産生促進剤 |
WO2015067791A1 (en) | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
US9618507B2 (en) | 2014-02-24 | 2017-04-11 | Betanien Hospital | Methods of treating rheumatoid arthritis |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
PL228341B1 (pl) * | 2014-04-21 | 2018-03-30 | Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia | Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu |
EP3185881B1 (en) * | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
ES2896971T3 (es) | 2014-11-21 | 2022-02-28 | Ascendis Pharma Endocrinology Div A/S | Formas de administración de hormona del crecimiento de acción prolongada |
JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー/エス | 極性の組換え延長部を有するインスリン |
TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
EP3347874B1 (en) * | 2015-09-09 | 2021-05-12 | Technische Universiteit Eindhoven | Imaging of dispersion and velocity of contrast agents |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
EP3359577A4 (en) * | 2015-10-08 | 2019-04-17 | The Governors of the University of Alberta | HEPATITIS C VIRUS E1 / E2 HETERODIMERS AND METHODS OF PRODUCING THE SAME |
US11401305B2 (en) * | 2015-12-22 | 2022-08-02 | Xl-Protein Gmbh | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |
US11123405B2 (en) | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
EP3400020A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
PL3400019T3 (pl) | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
SG11201805026SA (en) | 2016-01-08 | 2018-07-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
ES2929347T3 (es) | 2016-01-20 | 2022-11-28 | Merz Pharma Gmbh & Co Kgaa | Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto |
EP3423103A1 (en) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases A/S | Pth prodrugs |
KR20180114891A (ko) | 2016-03-02 | 2018-10-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소를 포함하는 조성물 |
US11306130B2 (en) | 2016-04-01 | 2022-04-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | PAR3 mimetic peptides and uses thereof |
EP3452097A1 (en) * | 2016-05-04 | 2019-03-13 | Navigo Proteins GmbH | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
WO2018011266A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
CN117257922A (zh) | 2016-09-29 | 2023-12-22 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
CN109843295B (zh) | 2016-09-29 | 2022-04-05 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
US11807671B2 (en) * | 2016-11-16 | 2023-11-07 | Auckland Uniservices Limited | Methods for protein ligation and uses thereof |
WO2018185131A2 (en) | 2017-04-05 | 2018-10-11 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
WO2018233813A1 (en) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION |
EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
AU2018287145B2 (en) * | 2017-06-21 | 2024-04-18 | Jazz Pharmaceuticals Ireland Limited | Modified L-asparaginase |
WO2018234455A1 (en) | 2017-06-21 | 2018-12-27 | Xl-Protein Gmbh | CONJUGATES OF PROTEIN MEDICINAL PRODUCTS AND PEPTIDES M / S |
US11155802B2 (en) | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
EP3483619A1 (en) * | 2017-11-13 | 2019-05-15 | Technische Universität München | Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg |
EP3713595A1 (en) * | 2017-11-22 | 2020-09-30 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
US20190184028A1 (en) * | 2017-12-14 | 2019-06-20 | Janssen Biotech, Inc. | Targeting with firbronectin type iii like domain molecules |
GB201804092D0 (en) * | 2018-03-14 | 2018-04-25 | Imperial Innovations Ltd | Methods and compositions |
WO2019185706A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
AU2019246389A1 (en) | 2018-03-28 | 2020-08-27 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
KR20210013584A (ko) | 2018-05-18 | 2021-02-04 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 개시 용량 |
MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
CA3137395A1 (en) * | 2019-01-10 | 2020-07-16 | Roswell Biotechnologies Inc. | Conductive synthetic peptides for molecular electronics |
US20220088149A1 (en) | 2019-02-11 | 2022-03-24 | Ascendis Pharma Bone Diseases A/S | Liquid Pharmaceutical Formulations of PTH Conjugates |
EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
US20220088147A1 (en) | 2019-03-04 | 2022-03-24 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
EP3714909A1 (en) * | 2019-03-28 | 2020-09-30 | Industrie Biomediche Insubri S.A. | Improved bone implant matrix comprising proline-rich peptide and method of preparing the same |
US10784093B1 (en) * | 2019-04-04 | 2020-09-22 | Thermo Finnigan Llc | Chunking algorithm for processing long scan data from a sequence of mass spectrometry ion images |
WO2020254602A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
AU2020295721A1 (en) | 2019-06-21 | 2021-12-23 | Ascendis Pharma A/S | Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds |
CA3143442A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
CA3152665A1 (en) | 2019-08-27 | 2021-03-04 | Tonix Pharma Limited | Modified tff2 polypeptides |
WO2021113434A1 (en) * | 2019-12-03 | 2021-06-10 | Rodan & Fields, Llc | Peptides and compositions for inhibiting hair growth |
JP2023512427A (ja) | 2020-01-03 | 2023-03-27 | アセンディス ファーマ エー/エス | 分子内転位を受けるコンジュゲート |
WO2021144249A1 (en) | 2020-01-13 | 2021-07-22 | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism treatment |
GB202007106D0 (en) * | 2020-05-14 | 2020-07-01 | Ucl Business Plc | Cyclosporine analogues |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
AU2021319863A1 (en) | 2020-08-05 | 2023-02-16 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
IL301411A (en) | 2020-09-28 | 2023-05-01 | Ascendis Pharma Bone Diseases As | Improving the physical and mental condition of patients with hypoparathyroidism |
KR20230124637A (ko) | 2020-12-22 | 2023-08-25 | 엑스엘-프로테인 게엠베하 | 구조적으로 무질서한 서열에 대해 특이적인 항체 |
CN112843222B (zh) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用 |
KR20230164709A (ko) | 2021-04-01 | 2023-12-04 | 아센디스 파마 에이에스 | 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도 |
AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI92601C (fi) | 1992-03-11 | 1994-12-12 | Marja Makarow | Menetelmä hyötyproteiinien erittämiseksi hiivoista |
US6639050B1 (en) * | 1997-07-21 | 2003-10-28 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
CA2412882A1 (en) | 2000-06-30 | 2002-01-10 | Maxygen Aps | Peptide extended glycosylated polypeptides |
US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
US20060252120A1 (en) * | 2003-05-09 | 2006-11-09 | Kieliszewski Marcia J | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
EP1734994A1 (en) | 2004-03-15 | 2006-12-27 | Trimeris, Inc. | Site-specific chemical modification of hiv gp41-derived peptides |
WO2005103235A1 (ja) * | 2004-04-19 | 2005-11-03 | Denka Seiken Co., Ltd. | ウイルスの生産方法 |
JP5735194B2 (ja) | 2005-01-25 | 2015-06-17 | セル セラピューティクス インコーポレーテッド | 改善された生体内半減期を有する生物学的に活性なタンパク質 |
SI2402754T2 (sl) | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Nestrukturirani rekombinantni polimeri in njihove uporabe |
US20100203083A1 (en) * | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
EP2440241B1 (en) | 2009-06-08 | 2017-08-09 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN102883734B (zh) | 2010-05-21 | 2018-01-02 | Xl-蛋白有限责任公司 | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 |
-
2011
- 2011-05-20 CN CN201180022849.3A patent/CN102883734B/zh active Active
- 2011-05-20 CA CA2794614A patent/CA2794614C/en active Active
- 2011-05-20 US US13/697,569 patent/US9221882B2/en active Active
- 2011-05-20 PL PL11725656T patent/PL2571510T3/pl unknown
- 2011-05-20 JP JP2013510644A patent/JP5828889B2/ja active Active
- 2011-05-20 SI SI201131597T patent/SI2571510T1/sl unknown
- 2011-05-20 MX MX2012013286A patent/MX338914B/es active IP Right Grant
- 2011-05-20 NZ NZ602522A patent/NZ602522A/en unknown
- 2011-05-20 DK DK11725656.0T patent/DK2571510T3/en active
- 2011-05-20 EP EP11725656.0A patent/EP2571510B1/en active Active
- 2011-05-20 SG SG2012081733A patent/SG185440A1/en unknown
- 2011-05-20 AU AU2011254564A patent/AU2011254564B2/en active Active
- 2011-05-20 WO PCT/EP2011/058307 patent/WO2011144756A1/en active Application Filing
- 2011-05-20 LT LTEP11725656.0T patent/LT2571510T/lt unknown
- 2011-05-20 EA EA201291010A patent/EA024755B1/ru unknown
- 2011-05-20 BR BR112012029577-2A patent/BR112012029577B1/pt active IP Right Grant
- 2011-05-20 MX MX2016005860A patent/MX357674B/es unknown
- 2011-05-20 ES ES11725656.0T patent/ES2691642T3/es active Active
- 2011-05-20 KR KR1020127030156A patent/KR101872541B1/ko active IP Right Grant
- 2011-05-20 CN CN201510649876.3A patent/CN105477641B/zh active Active
- 2011-05-20 EP EP18184601.5A patent/EP3473261A1/en not_active Withdrawn
-
2015
- 2015-07-31 JP JP2015152081A patent/JP6038248B2/ja active Active
- 2015-11-12 US US14/939,626 patent/US10081657B2/en active Active
-
2016
- 2016-07-11 HK HK16108081.5A patent/HK1219902A1/zh unknown
-
2018
- 2018-08-21 US US16/107,590 patent/US10844094B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219902A1 (zh) | 生物合成的脯氨酸/丙氨酸無規捲曲多肽及其用途 | |
HRP20191852T8 (hr) | Polipeptidi | |
ZA201303134B (en) | Modified factor ix polypeptides and uses thereof | |
HK1189587A1 (zh) | 溴結構域蛋白抑制劑及其應用 | |
HK1182719A1 (zh) | 多肽 | |
EP2645387A4 (en) | LOAD CONTROL SWITCH AND LOAD CONTROL SWITCH SYSTEM | |
IL222027A (en) | Peptides and their use | |
GB0916578D0 (en) | Polypeptides and uses thereof | |
ZA201200716B (en) | Modified factor ix polypeptides and uses thereof | |
EP2483292A4 (en) | LOVD VARIANT POLYPEPTIDES AND USES THEREOF | |
GB0916576D0 (en) | Polypeptides and uses thereof | |
EP2593595A4 (en) | NOVEL PEPTIDES AND USES THEREOF | |
PL2588491T3 (pl) | Nowy peptyd i jego zastosowanie | |
EP2513137A4 (en) | PEPTIDES DERIVED FROM SAPOSINE-A AND USES THEREOF | |
PL2627668T3 (pl) | Peptydy i ich zastosowanie | |
SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
EP2660249A4 (en) | PEPTIDE DERIVATIVE AND USE THEREOF | |
PT2571510T (pt) | Polipéptidos biossintéticos de prolina/alanina de hélice aleatória e suas utilizações | |
EP2415780A4 (en) | SYNTHETIC PEPTIDE AND USES THEREOF |